Results

Merck & Co. Inc.

05/05/2021 | Press release | Distributed by Public on 05/05/2021 14:12

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive[...]